Results 41 to 50 of about 1,158 (177)

Case Report: Morphologic and Functional Characteristics of Intestinal Mucosa in a Child With Short Bowel Syndrome After Treatment With Teduglutide: Evidence in Favor of GLP-2 Analog Safety

Frontiers in Nutrition, 2022
Teduglutide is a glucagon-like peptide-2 (GLP-2) analog employed in patients with short bowel syndrome (SBS) to reduce the need of parenteral nutrition in these patients, by virtue of its effects on enteric function.
Enrico Costantino Falco, Antonella Lezo, Pierluigi Calvo, Caterina Rigazio, Anna Opramolla, Ludovica Verdun, Giovanna Cenacchi, Marianna Pellegrini, Marco Spada, Gabriella Canavese   +9 more
doaj   +1 more source

Teduglutide for treatment-refractory severe intestinal acute graft-versus-host disease - a multicenter survey. [PDF]

Bone Marrow Transplant
Intestinal glucocorticoid-refractory (SR) acute (a) graft-versus-host disease (GVHD) causes high non-relapse mortality (NRM) in patients after allogeneic hematopoietic cell transplantation (allo-HCT).
Brehm N, Biavasco F, Clausen J, Jung J, Maas-Bauer K, Wäsch R, Verbeek M, Nuernbergk C, Ihorst G, Seropian S, Finke J, Gowda L, Sidlik Muskatel R, Peffault de Latour R, Socie G, Wehr C, Michonneau D, Zeiser R.   +17 more
europepmc   +2 more sources

Safety and efficacy of teduglutide therapy for management of short bowel syndrome after intestinal transplantation

, 2021
Introduction: Intestinal transplantation is a rare surgical procedure performed on patients with severe short bowel syndrome, characterized by inadequate intestinal absorption.
Nassar, Sami I, Jafri, Syed-Mohammed
core   +1 more source

Innovative technologies in the treatment of short bowel syndrome

Медицинский совет, 2022
Introdiction. In recent years, many new technologies for the management of patients with short bowel syndrom (SBS), including SBS-IF (short bowel syndrom with intestinal failor), have appeared.
L. N. Kostyuchenko, A. V. Leontiev, M. V. Kostyuchenko, A. E. Lychkova, T. A. Vasina, M. N. Puzin   +5 more
doaj   +1 more source

Efficacy and Safety of Teduglutide in Infants and Children With Short Bowel Syndrome Dependent on Parenteral Support

, 2023
Objectives: Our objective was to evaluate the short-and long-term safety and efficacy of teduglutide treatment in infants and children with short bowel syndrome with intestinal failure (SBS-IF).Methods: Two open-label phase 3 studies and 1 extension ...
Protheroe, Susan, Motoshi Wada, Morii, Mayako, Sakui, Sho, Toshiharu Matsuura, Kouji Masumoto, Sho Sakui, Udagawa, Eri, Urs, Arun, Arun Urs, Szu-Ta Chen, Mikko P. Pakarinen, Pakarinen, Mikko P., Chen, Szu-Ta, Tatsuru Kaji, Masumoto, Kouji, Chiba, Masahiro, Andrew Fagbemi, Mayako Morii, Hill, Susan, Masahiro Chiba, Susan Protheroe, Kaji, Tatsuru, Wada, Motoshi, Susan Hill, Fagbemi, Andrew, Matsuura, Toshiharu, Eri Udagawa   +27 more
core   +1 more source

Endogenous glucagon-like peptide- 1 and 2 are essential for regeneration after acute intestinal injury in mice. [PDF]

PLoS ONE, 2018
OBJECTIVE:Mucositis is a side effect of chemotherapy seen in the digestive tract, with symptoms including pain, diarrhoea, inflammation and ulcerations.
Rasmus Hytting-Andreasen, Emilie Balk-Møller, Bolette Hartmann, Jens Pedersen, Johanne Agerlin Windeløv, Jens Juul Holst, Hannelouise Kissow   +6 more
doaj   +1 more source

Delayed presentation of a retained colonic segment in a child with intestinal failure on teduglutide. [PDF]

JPGN Rep
Abstract Teduglutide is a glucagon‐like peptide 2 (GLP‐2) analogue that was approved by the United States Food and Drug Administration for the treatment of pediatric (>1 year) intestinal failure due to short bowel syndrome in 2019. GLP‐2 analogues promote rapid intestinal adaptation, increasing the absorptive capacity of residual intestine after ...
Bordelon RC, Varalla SJ, Tammisetti VS, Shahin MM, Tchakarov A, Imseis E, Speer AL.   +6 more
europepmc   +2 more sources

Effects of Teduglutide on Diarrhea in Pediatric Patients with Short Bowel Syndrome-Associated Intestinal Failure

, 2023
Objectives: This post hoc analysis evaluated the effect of teduglutide treatment on diarrhea in patients with short bowel syndrome-associated intestinal failure (SBS-IF).
Sharif Uddin, Brian Terreri, Uddin, Sharif, Fifi, Amanda, Kaufman, Stuart S., Stuart S. Kaufman, Bram P. Raphael, Raphael, Bram P., Terreri, Brian, Amanda Fifi   +9 more
core   +1 more source

Alveolar Rhabdomyosarcoma in a 69-Year-Old Woman Receiving Glucagon-Like Peptide-2 Therapy

Case Reports in Oncological Medicine, 2015
A 69-year-old woman was diagnosed with alveolar rhabdomyosarcoma (ARMS) of the nasopharynx. She has a history of catastrophic thromboembolic event in the abdomen that caused short-gut syndrome and dependence on total parenteral nutrition (TPN) twelve ...
Laura E. Zyczynski, Jonathan B. McHugh, Thomas E. Gribbin, Scott M. Schuetze   +3 more
doaj   +1 more source

Intestinal Epithelial Stem Cells: Distinct Behavior After Surgical Injury and Teduglutide Administration

Journal of Investigative Surgery, 2018
Background: Previous studies suggest that intestinal epithelial stem cells (IESC), critical drivers of homeostasis and regeneration, include two subpopulations: crypt-based columnar and “position +4” stem cells, identified by Lgr5 and Bmi1 biomarkers ...
Beatriz P. Costa, Ana C. Gonçalves, Ana M. Abrantes, Raquel Alves, Paulo Matafome, Raquel Seiça, Ana B. Sarmento-Ribeiro, M. Filomena Botelho, Francisco Castro-Sousa   +8 more
doaj   +1 more source